The four phase 3 obesity trials of retatrutide that have reported results, with the population, comparator, dose arm labels, source and date for each.
Phase 2Published Aug 2023
Phase 34 trials reported, Dec 2025 to Jul 2026
SubmissionLilly plans Q1 2027. Not made yet.
FDA reviewNo date exists
ApprovalUnknown
This page covers the Phase 3 stretch of the road: the four trials that have reported, and the studies still running.
Read this before comparing. These trials enrolled different people, ran for different lengths of time and used different analyses. Do not compare one trial's number with another's as if the drug was tested head to head. The only head-to-head study against another drug (TRIUMPH-5, tirzepatide) has no results yet. Dose arms are study labels, not recommendations. All four trials were sponsored and funded by Eli Lilly and Company.
The four trials
Phase 3 trials with reported results, as of 2026-11-19, in trial order. Weight change is the mean percent change from baseline. Each chart shows one trial only.
Adults with obesity or overweight and at least one weight-related condition, without diabetes. 2,339 randomized (Lilly release; the registry lists 2,335 actual enrollment).
Comparator and dose arm labels
Placebo. Retatrutide 4 mg, 9 mg, 12 mg.
Duration
80 weeks (a 104-week extension in a subgroup)
Mean percent weight change from baseline, efficacy estimand, each arm against this trial's own placebo
4 mg
−19.0%
9 mg
−25.9%
12 mg
−28.3%
Placebo
−2.2%
0%−10%−20%−30%
Headline result
Efficacy estimand: 4 mg −19.0%, 9 mg −25.9%, 12 mg −28.3%, placebo −2.2%. Treatment-regimen estimand (also in the journal): −17.6%, −23.7%, −25.0% vs −3.9%.
Adults with severe obesity (BMI of 35 or more) and established cardiovascular disease, with or without type 2 diabetes. 1,949 randomized (registry: 1,946 actual enrollment).
Comparator and dose arm labels
Placebo. Retatrutide 9 mg, 12 mg.
Duration
80 weeks
Mean percent weight change from baseline, efficacy estimand, each arm against this trial's own placebo
Adults with obesity or overweight (BMI of 27 or more) and knee osteoarthritis, without diabetes. 445 randomized.
Comparator and dose arm labels
Placebo. Retatrutide 9 mg, 12 mg.
Duration
68 weeks
Mean percent weight change from baseline, efficacy estimand, each arm against this trial's own placebo
9 mg
−26.4%
12 mg
−28.7%
Placebo
−2.1%
0%−10%−20%−30%
Headline result
Efficacy estimand: 9 mg −26.4%, 12 mg −28.7%, placebo −2.1%. Treatment-regimen estimand (also in the journal): −20.0%, −23.7% vs −4.6%. Knee pain (WOMAC) also fell more than on placebo.
An estimand is the question a trial analysis answers. An efficacy estimand estimates the effect if participants stayed on treatment. A treatment-regimen estimand estimates the effect of being assigned to treatment, including people who stopped or switched. The treatment-regimen figures are lower. Both are shown because the sponsor leads with the first and the journal articles report the second.
Stopping treatment because of side effects
Share of participants who stopped the study drug because of an adverse event, as reported by Lilly. Each row is one trial, with its own population and length. Rows are not comparable with each other.
Discontinuation due to adverse events, sponsor toplines
The TRIUMPH-1 journal article states that the most common adverse events were gastrointestinal. A full side-effects page will follow when the figures can be checked against the journal papers and reviewed.
Official study records
Every registered trial has a public record on ClinicalTrials.gov, the US National Library of Medicine registry. Records show who sponsors the study, who may join, where it runs and its status. The four records above are linked in each trial. Other Lilly phase 3 retatrutide records on the registry, as read on 2026-11-19:
Other phase 3 records (status and primary completion date as shown on the registry)
Type 2 diabetes with moderate or severe kidney impairment, versus placebo
Active, not recruiting
2026-10-26
Registry entries change. Open the record for the current status. TRIUMPH-5 record last updated 2026-07-20.
What the status words mean
Recruiting: the study is enrolling people now.
Active, not recruiting: enrollment has closed; participants are still being treated or followed.
Completed: follow-up has ended. Results may not be public yet. The sponsor or a journal publishes them separately.
Joining a trial has eligibility rules and risks. Ask a clinician. This site does not recruit for any study.
Frequently asked questions
What does "recruiting" mean on ClinicalTrials.gov?
Recruiting means the study is currently enrolling participants. "Active, not recruiting" means it has stopped enrolling but is still running. "Completed" means participant follow-up has ended. Completed does not mean results have been posted or published.
Are the TRIUMPH results peer reviewed?
TRIUMPH-1 and TRIUMPH-4 have been published in the New England Journal of Medicine (2026-09-29 and 2026-11-08). For TRIUMPH-2 and TRIUMPH-3 we found only the sponsor topline release of 2026-07-23 as of 2026-11-19.
Is there a trial comparing retatrutide with tirzepatide?
ClinicalTrials.gov lists TRIUMPH-5 (NCT06662383), a phase 3 comparison with tirzepatide. As of the record last updated 2026-07-20 it was active, not recruiting, with an estimated primary completion in November 2026. We found no results for it as of 2026-11-19.
Sources used on this page
Eli Lilly and Company releases: 2025-12-11 (TRIUMPH-4), 2026-05-21 (TRIUMPH-1), 2026-07-23 (TRIUMPH-2 and 3). Lilly's own site could not be read by our tools, so we used the identical text distributed through PR Newswire and BioSpace.
Journal: N Engl J Med, DOI 10.1056/NEJMoa2604169 and 10.1056/NEJMoa2610676 (abstracts read via PubMed and Crossref).
ClinicalTrials.gov records, read through the registry's public data service on 2026-11-19.